<DOC>
	<DOCNO>NCT02383108</DOCNO>
	<brief_summary>A two-arm , Phase 2/3 multicentre , open-label , randomise study evaluate safety antiviral effect current standard antiretroviral therapy compare elvitegravir ( EVG ) administer darunavir/ritonavir ( DRV/r ) HIV-1 infect , virologically suppress paediatric participant .</brief_summary>
	<brief_title>Strategy Maintenance HIV Suppression With Elvitegravir + Darunavir/Ritonavir Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>HIV1 infect child weigh â‰¥ 17 kg screen visit Parents guardian , child appropriate , willing able give inform consent adhere protocol Children must HIV1 RNA viral load &lt; 50c/mL least 12 month minimum two separate result screen . Children 3drug PI/r NNRTI contain regimen least 6 month . Children/parents/guardians prepared switch randomise elvitegravir + darunavir/ritonavir arm Children parent prepare restart current ART regimen simplification viral load restart criterion meet ( see Section 5.5 ) For child age 612 either : child caregiver willing participate leadin PK study child age 612 PK study still enrol child weight band* OR Data leadin PK study analyse child age 612 enrol directly main study * child randomise Arm 1 take part Receiving require agent interaction darunavir , RTV , EVG Evidence resistance DRV integrase inhibitor ( participant clinical site resistance test standard care ) Previous exposure integrase inhibitor 2 week History previous encephalopathy Intercurrent illness ( randomisation take place illness resolve ) Creatinine , AST ALT grade 3 screening . Diagnosis tuberculosis antituberculosis treatment ( child enrol successful tuberculosis treatment ) Hepatitis B Hepatitis C coinfection Pregnancy risk pregnancy girl childbearing potential unless commit take effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>